Avacincaptad pegol sodium

Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system .


Cat. No.: EX-A8417E	Purity: >98%

	Chemical structure of Avacincaptad pegol sodium

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order
1g	get quote	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	1491144-00-3
Purity	>98%
Color	white to off-white
State	solid powder
Solubility	H2O : 100 mg/mL
Shelf Life	>1 years if stored properly
Storage	-20°C, protect from light
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1].Joshua Ong, et al. The Complement System as a Therapeutic Target in Retinal Disease. Medicina (Kaunas). 2024 Jun 5;60(6):945. [2].Yiming Li, et al. Targeting both C5 and HTRA1 provides additional rescue effect in NaIO3-induce GA model. IOVS. June 2024, Vol.65, OD68. [3].Aira Sarkar, et al. Novel and investigational therapies for wet and dry age-related macular degeneration. Drug Discov Today. 2022 Aug;27(8):2322-2332. [4].Padma Sundaram, et al. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci. 2013 Jan 23;48(1-2):259-71. [5].Thomas Ryan Jarrett, et al. Material Trends and Clinical Costings in Systematically Identified CDER-Approved Nanomedicines. Advanced Therapeutics. 02 September 2024.
CoA	CoA of Avacincaptad pegol sodium


		Search